cyrilzakka/clinical-trials huggingface dataset:
24-hour Movement Behaviors Among Normal Weight, Overweight and Obese Adults

The prevalence of adults with overweight (50%) and obesity (15%) reached high number in Belgium. Important lifestyle behaviors, i.e. sleep, sedentary time (SB), and physical activity (PA) subdivided into light physical activity (LPA) and moderate to vigorous physical activity (MVPA), have shown an impact on overweight and obesity characteristics (e.g. adiposity). However, these behaviors have often been investigated separately. Therefore, a recent shift in research emphasizes the importance of considering these behaviors as part of a 24-hour day.

Since these adults can benefit from an optimal 24-hour composition as part of a healthy lifestyle, it may be interesting to investigate the 24-hour movement composition among these adults. In addition, exploring different personal determinants, environmental determinants, and cardiometabolic markers will provide meaningful insights in developing an intervention.


Eligibility Criteria:
Inclusion criteria OwOb group

* Adults aged 25-64 years
* Active on the job market for at least 50 percent
* BMI ≥25kg/m² and Waist Circumference C ≥94cm for men and ≥80 cm for women

Inclusion criteria Nw participants

* Adults aged 25-64 years
* Active on the job market for at least 50 percent
* BMI \<25kg/m² and Waist Circumference \<94cm for men and \<80 cm for women

Exclusion criteria Nw, Ow, Ob patients

* Retirement and early retirement
* Unemployment
* Working for less than 50 percent
* Working in night shifts
* Physical (e.g. amputations, paralysis, recovering from stroke, osteoarthritis), cognitive (e.g. dementia, psychological disorders) and major medical (e.g. Chronic respiratory diseases, heart failure, cardiovascular diseases) conditions that obstruct daily functioning
* Taking diabetes related medication
* Active treatment for cancer
* Pregnancy
* Breastfeeding
* Pregnancy \<1 year ago
* Currently involved in study specific weight loss interventions
* Waitlist for weight loss surgery
* Weight loss surgery \<1 year ago
* Taking medication which affects your body weight (e.g. thyroid medication, psychotropic medication)
* Thyroid problems which affects your body weight
* Hospitalized
Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women

Polycystic ovarian syndrome (PCOS) is a condition characterized by infertility, infrequent periods and amenorrhea or irregular bleeding plus anovulatory infertility. Clomid is the standard first drug of treatment for ovulation induction. Ovulation and conception will occur in approximately 75 and 30 percent of cases respectively. Cases not ovulating in response to doses of clomid up to 150 mg/day are known as clomid resistant PCOS.

To test whether CC co- treatment with chronic low dose HP uFSH versus lirizole plus chronic low dose HP uFSH in CC resistant PCOS will yield comparable results in terms of, ovulation rate, lower follicle number, lower HP uFSH dose, better outcome in terms of pregnancy rates, better cost-effectiveness ratio, lower multiple pregnancy rates, lower cycle cancellation.

Eligibility Criteria:
Inclusion Criteria:

* CC resistant PCOS
* Infertile
* Females
* Age 18-38

Exclusion Criteria:

* Hyperprolactinaemia
* Cushing syndrome
* Adult onset adrenal hyperplasia
* Age \> 38
* Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.

The study includes 2 treatment periods. The open-label run-in period will begin at patient enrolment and continue for 3 weeks, during which all patients will receive once daily treatment with zicronapine. The double-blind period will begin at patient randomization and continue for 5 weeks, during which the patients will be assigned to one group receiving once daily treatment with zicronapine and 3 groups receiving once weekly treatment with zicronapine.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)
* A score of \<=4 (moderately ill) on Clinical Global Impression - Severity of Illness (CGI-S) scale
* A total score \>=60 on Positive and Negative Syndrome Scale (PANSS)
* A score of \<=4 (moderate) on PANSS items: P7 (hostility) AND G8 (uncooperativeness)

Exclusion Criteria:

* Acute exacerbation requiring hospitalization within the last 3 months OR requiring change of antipsychotic medication within the last 4 weeks
* Diagnosis or history of substance dependence or substance abuse according to DSM-IV-TR within the last 3 months
* Significant risk of harming himself/herself or others
* Positive serology for hepatitis A, B, C, or HIV
* Present condition that might compromise liver function
* Medical or neurological disorder or treatment that could interfere with study treatment or compliance
* Previous exposure to zicronapine

Other inclusion and exclusion criteria may apply.
EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis

The goal of this prospective study is to evaluate the feasibility of the Core Biopsy Needle with reverse bevel (Procore TM) in diagnosing autoimmune pancretitis


Eligibility Criteria:
Inclusion Criteria:

* patient age 18 years and older
* patients with suspicion of autoimmune pancreatitis (based on the findings in EUS and MRI)

Exclusion Criteria:

* unable to obtain informed consent
* ASA class 4 and 5
* known pregnancy
* contraindication for endoscopy or for biopsy sampling
* patients with high suspicion on pancreatic cancer (based on the findings in radiology and EUS)
Improving Emotion Regulation in Adolescents With ADHD

The purpose of our study is to examine the impact of a program that provides emotion regulation skills for adolescents aged 11-16 with Attention-Deficit/Hyperactivity Disorder (ADHD) and poor emotion regulation. The program is called RELAX (Regulating Emotions Like An eXpert). RELAX is an experimental intervention that may equip adolescents with emotion regulation and conflict management skills and includes parent involvement to help parents support adolescents' use of these skills.

Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly 90-minute group sessions and 1 booster session 8 weeks after the completion of the RELAX intervention. The first 60 minutes of each group involve separate parent and adolescent groups. Adolescents (ages 11-16) attend an emotion regulation and conflict management skills group, while parents attend a group focused on how to support utilization of these skills in adolescents at home and school through use of modeling their own emotion regulation skills and use of supportive emotion socialization practices. For the final 30 minutes of the session, parents and adolescents combine and complete a collaborative activity and skill rehearsal homework is discussed for the week. Homework will be discussed at the beginning of the separate group meetings the following week. The primary overall goal of the RELAX intervention is to assist adolescents and parents in traveling down the Path of RELAXation by working on the three C's (communication, coping, and conflict management skills). A multimethod assessment of emotional, social, and family functioning will be assessed pre- and post-intervention and at an 8 week follow-up.

Eligibility Criteria:
Inclusion Criteria (adolescents):

* ADHD diagnosis
* parent-reported emotion regulation in the clinical range
* full scale intelligence quotient ≥80
* English as a primary language
Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function

This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.

In women with endometrioma who plan to undergo laparoscopic ovarian cystectomy, surgical technique can influence postoperative ovarian function because of removal of normal ovarian tissue with ovarian cyst and damage to ovarian tissue during bleeding control after stripping of endometrioma. This study is designed to compare hemostatic sealant to suturing in terms of hemostatic function, safety and preservation of ovarian function.

Ovarian function of all patients will be evaluated on pre op, post op 12 weeks, post op 48 weeks by measuring AMH and ovarian volume. And Hemostatic function will be evaluated by measuring serum hemoglobin, blood loss during operation, etc.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent.
* Age: 19-45 year-old women
* American Society of Anesthesiologists Physical Status classification 1 or 2
* Plan of laparoscopic ovarian cystectomy for unilateral or bilateral ovarian endometriosis diagnosed by ultrasonography
* Regular menstruation every 21-45 days

Exclusion Criteria:

* No 'ovarian' endometriosis
* Suspicious disease of ovarian malignancy
* Age: 18 and younger, 46 and older
* Pregnancy or breastfeeding.
* Lower than 0.05 ng/ml of serum Anti-mullerian hormone level
* Hormonal therapy within recent 3 months
* Considered as inappropriate by the researcher's judgment.
Desogestrel-containing COCP Pharmacokinetic Validation Study

This study aims to validate prior pharmacokinetic research with combined oral contraceptive pill users that supports utilizing a 24-hour trough concentration as an accurate proxy for the intensive pharmacokinetic parameter of area under the curve (gold standard pharmacokinetics). The original pharmacokinetic studies were performed with a levonorgestrel-containing oral contraceptive pill and we aim to duplicate those findings with a desogestrel-containing oral contraceptive pill.

Enrolled participants will be started on a standard pack of desogestrel-containing oral contraceptive pills and undergo an intensive pharmacokinetic study visit on day 21 of the pill pack. This will entail 11 serial blood draws and a final blood draw the next day at 24 hours post-pill intake to measure and calculate a pharmacokinetic area under the curve for both the estrogen and progestin components of the pill. We will then correlate the 24-hour trough measurement to the area under the curve measures to determine the correlation of these measurements.

Eligibility Criteria:
Inclusion Criteria:

* Healthy females aged 18-45 years
* Body-mass index ≥18.5kg/m2
* Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study
* Normal blood pressure measurement at screening (systolic \<140mmHg, diastolic \<90mmHg)
* Negative urine pregnancy test at screening

Exclusion Criteria:

* Currently taking any known CYP3A4 inducers/inhibitors
* Medical conditions that affect liver function (e.g. hepatitis, cirrhosis)
* Any contraindications to estrogen-containing contraception (based on any category 3 or 4 recommendations from the CDC MEC guidelines)
* Use of an injectable contraceptive method within the last 6 months or current use of an ENG contraceptive implant
* Childbirth within the last 6 months
* Known allergy or insensitivity to combined oral contraceptive pills
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

This pilot study compares three photosensitisers, hexylaminolevulinate (HAL) and aminolevulinic acid nano emulsion (BF-200 ALA) to methylaminolevulinate (MAL) in photodynamic therapy of superficially growing basal cell carcinomas. Study is conducted using randomised prospective double blinded comparing design. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up before and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.

Study recruits volunteering patients, who are referred to the department of dermatology and allergology, Päijät-Häme Central Hospital, Lahti, with 99 clinically assessed superficial basal cell carcinoma on the body area, not face and scalp. Diagnoses is confirmed histologically by punch biopsies and hyperspectral images are taken before the biopsies. The lesions are randomised in three groups: interventions HAL and BF-200 ALA and comparator MAL. Photodynamic therapy is given by the standard procedure. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up, with Wood's light, digital camera and a yellow lens, before and after the exposure. Pain is measured in VAS-scale before, during and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.

Eligibility Criteria:
Inclusion Criteria:

* superficial basal cell carcinomas on body area (clinically assessed to be mainly superficially growing and later on a biopsy proven sBCC or thin nBCC)
* lesions accepted needs to be 10 cm apart from each other

Exclusion Criteria:

* pigmented, morpheaform, infiltrative or nodular basal cell carcinomas
* lesions that are in face and scalp area
* pregnancy
* breast feeding
* allergy to photosensitizer
* phorphyria or photosensitivity
18751-Sun Protection Factor Assay.

To evaluate the Sun Protection Factor (SPF) efficacy on human skin.


Eligibility Criteria:
Inclusion Criteria: - Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. - Male or female - Aged between 18-70 years old. - Good health - Signed and dated Informed Consent Form - Signed and dated Health Insurance Portability and Accountability Authorization (HIPAA) Form - An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: - Subjects on test at any other research laboratory or clinic. - Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. - PRe-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study. - Pre-existing other medical conditions (e.g. adult asthma. diabetes). - Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. - Treatment with antibiotics within two weeks prior to initiation of the test - Chronic medication which could affect the results of the study. - Known pregnant or nursing women.
Non-invasive Measurement of CO in Patients With Uncomplicated Sepsis

Little is known about the optimal fluid therapy of patients with uncomplicated sepsis. Most recommendations are extrapolated from studies performed in patients with septic shock. Therefore, it is unknown how effective our current fluid therapy is. Furthermore, current therapy is not tailored to individual needs. The aim of the current study is to investigate the added value of non-invasive measurements of (dynamic) circulatory parameters in the treatment of a convenience sample of sepsis patients presenting to the ED.


Eligibility Criteria:
Inclusion Criteria:

At presentation in the ED:

* there has to be evidence of an infection: -temp \<36 or \>38 without an obvious cause for hypo-or hyperthermia
* There has to be evidence of organ dysfunction by the presence of at least one of the following criteria: altered mental state, hypoxia (spo2\<94% or 5% lower than baseline), lactate \>2 mmol/l in ABGA or VBGA directly drawn after presentation, hypotension (MAP\<65 mmHg or SBP\<100mmHg), or a respiratory rate\>22/min.

Exclusion Criteria:

* Age\<16
* Patients with septic shock (i.e. who remained hypotensive after fluid bolus administration, needing vasopressor therapy to obtain a MAP\>65 in the presence of a lactate \>2. (i.e. septic shock) These will be excluded afterwards, but will be shown in an inclusion flowchart.
* Subjects for whom it is impossible to obtain a reliable signal for Clearsight measurements.
* Increased abdominal pressures
* Need for immediate ventilatory support or surgery
* Presence of an acute cerebral event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, active gastrointestinal bleed, trauma
* Known metastatic cancer
* Pregnancy
Analysis of the NuStep as an Introductory Fitness Regimen

The purpose of this research study is to determine if participation in a fifteen week introductory exercise regimen using the NuStep by sedentary adults diagnosed with Type 1 or Type 2 diabetes will affect exercise adherence and lifestyle adjustment. This study will examine if using the NuStep encourages participants to seek other modes and facilitates interest in exercise. Age, gender, weight, height, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C will be recorded pre, mid-point, and post-test. During each NuStep exercise session heart rate, blood pressure, blood glucose level, oxygen saturation, METs, and the Borg rate of perceived exertion will be monitored.

Associations between NuStep use and exercise adherence are investigated through the following hypothesis and null hypothesis. There is an association between using the NuStep as an introductory exercise regimen by sedentary adults diagnosed with Type 1 or Type 2 diabetes and exercise adherence. The null hypothesis states there is no association between using the NuStep as an introductory exercise regimen by sedentary adults diagnosed with Type 1 or Type 2 diabetes and exercise adherence. The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise. Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.


Eligibility Criteria:
Inclusion Criteria:

* Sedentary adults diagnosed by a physician with Type 1 diabetes or Type 2 diabetes. Sedentary adults are defined as persons 19 years of age and older that are not meeting the minimal physical activity recommendations from the U.S. Surgeon General's report.

Exclusion Criteria:

* Adults with:

  * severe cardiovascular disease (high blood pressure, abnormal heart rhythm, peripheral artery disease, atherosclerosis, congestive heart failure, congenital heart disease, valvular heart disease and coronary artery disease)
  * amputees
  * severe foot ulcers
  * severe neuropathy
  * an amplified susceptibility to hypoglycemia
  * those weighing 400 lbs. or more, or inability to adequately perform exercise
Prevalence of Urinary Incontinence in Different Age Categories

Introduction: Urinary incontinence (UI) is considered erroneously by many as being a phenomenon of the aging process, however there is a growing prevalence of complaints of UI in nulliparous and nulligest young women.

Objective: To investigate the prevalence of urinary incontinence in women of different age groups.

Method: 78 nulliparous and nulligest women of different resident age groups in the city of France, being these divided in: G1 (10-18 years); G2 (20-35 years); G3 (45-60 years) and G4 (65-75 years). Excluded from this study were women with cancer or surgeries of the inferior urinary treatment, urinary infection, alterations cognitive, pregnant and obesity. All the participants were questioned as a perception of urine loss, to the efforts or effortlessly evident.

All participants were asked about perceived loss of urine, the effort or without apparent effort. The responses of participants from G1 were offered by parents and / or responsible.

Eligibility Criteria:
Inclusion Criteria:

* nulliparous and nulligest women

Exclusion Criteria:

* women with cancer reported
* surgeries of the inferior urinary treatment
* urinary infection
* cognitive alterations
* pregnant
* obesity
Glycemic Index of Longan Syrup in Healthy Volunteers

Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking.


Eligibility Criteria:
Inclusion Criteria:

* Ages 18-60 years
* Never diagnosis as diabetes mellitus of thyroid dysfunction
* Fasting plasma glucose less than 100 mg/dl
* Body mass index 18.5-24.9 kg/m2
* Be willing to be subjects in this study

Exclusion Criteria:

* Know longan allergy or have history of adverse events from longan
* Take medicines, herbs, or food supplements including thiazide diuretics, beta-blockers ,and estrogen that have an effect on blood sugar level in 1 month before this study starting
* Severe comorbidity or uncontrolled diseases
* Pregnancy and lactation
* Participated in other studies
Rituximab in Treating Patients With Hodgkin's Lymphoma

Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.

This study will evaluate the partial, complete, and overall response rates to rituximab of subjects with lymphocyte-predominant Hodgkin's lymphoma. Subjects will receive rituximab by IV infusion over several hours once a week for 4 weeks, followed by maintenance therapy as repeat course of the same dose and schedule rituximab at 6, 12, and 18 months.

This was a single-arm study with multiple treatment periods added by amendment (ie, Secondary Group), with results reported by treatment period. As this was always considered a single-arm study, there was no intent to report the results for the initial treatment period separately as the Initial Group vs the Secondary Group.

Eligibility Criteria:
INCLUSION CRITERIA

* Age ≥ 3 years
* Lymphocyte-predominant Hodgkin's disease (LPHD) of B-cell lineage
* Biopsy-confirmed expression of CD20 antigen
* At least one tumor mass measuring \> 1.0 cm in largest dimension
* No evidence of active infection
* Subjects at high risk of Hepatitis B virus (HBV) infection should be screened prior to enrollment.
* Performance status of 0 to 2
* Absolute neutrophil count (ANC) \> 1500/mL
* Platelet count \> 50,000/mL
* Serum creatinine (Cr) \< 1.5 x upper limit of normal (ULN)
* Alkaline phosphatase \< 2 x ULN, unless related to primary disease
* Bilirubin \< 2 x ULN, unless related to primary disease
* Aspartate transaminase (AST) and alanine transaminase (ALT) \< 2 x ULN, unless related to primary disease
* Subjects must be able to read and sign Institutional Review Board-approved informed consent

EXCLUSION CRITERIA

* Life expectancy at least 12 weeks
* Evidence of other active malignancies other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin
* Active HBV infection or hepatitis.
* Serious non-malignant disease (eg, congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections)
* Concomitant or treatment within prior 4 weeks with radiotherapy or chemotherapy (within prior 6 weeks for nitrosourea compounds)
* Concurrent treatment with prednisone or other systemic steroid medication
* Treatment with any investigational drug within 30 days prior to entry into the study
* Treatment with any investigational drug within 5 half-lives of that drug prior to entry into the study
* Major surgery, other than diagnostic surgery, within 4 weeks
* Any other conditions which, in the opinion of the investigator and/or sponsor, would compromise other protocol objectives
* Female patients must be of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry